Add Yahoo as a preferred source to see more of our stories on Google. Improvements testing models and the understanding of Parkinson's disease will help guide future drug development in the indication ...

The gut microbiome is a ripe target for future treatments that could potentially stop or slow PD progression at an early ...

For many individuals living with Parkinson's disease and those in its "prodromal" or early stages before movement impairment, there is a distressing gap between how they feel their brain is working ...

Parkinson’s Disease is a progressive neurological disorder that will eventually lead to a late or end‑stage with severe symptoms and complex care requirements. The phase needs to be addressed for ...

Up to 1 in 3 people with Parkinson's disease use at least one psychotropic medication, a recent study from the University of ...

Your T cells work hard to fight disease. Unfortunately, "friendly fire" from T cells can sometimes harm the body's healthy tissues. For people with autoimmune disease, T cell reactivity is a big ...

A few years ago, you mentioned a study on the idea that GLP-1 drugs might have a protective effect for people with ...

GOTHENBURG, SE / ACCESS Newswire / April 29, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, announced today that ...

Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial approaches remain critical barriers to innovation, says ...